Advertisements



Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 6.25% and 0.00%, respectively, f.....»»

Category: personnelSource: nytNov 8th, 2018

Melinta Therapeutics, Inc. (MLNT) Reports Q4 Loss, Tops Revenue Estimates

Zacks.....»»

Category: topSource: redinewsMar 13th, 2019

Cara Therapeutics (CARA) Reports Q4 Loss, Tops Revenue Estimates

Zacks.....»»

Category: topSource: redinewsMar 12th, 2019

Cara Therapeutics (CARA) Reports Q4 Loss, Tops Revenue Estimates

Cara (CARA) delivered earnings and revenue surprises of 11.86% and 65.26%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock? Want the latest recommendations from Zacks .....»»

Category: personnelSource: nytMar 12th, 2019

Spero Therapeutics (SPRO) Presents At Cowen And Company 39th Annual Health Care Conference - Slideshow

Spero Therapeutics (SPRO) Presents At Cowen And Company 39th Annual Health Care Conference - Slideshow.....»»

Category: topSource: seekingalphaMar 12th, 2019

Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue Estimates

Halo.....»»

Category: smallbizSource: nytFeb 21st, 2019

Spero Therapeutics reports "positive" feedback from FDA pre-Phase 3 meeting

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 7th, 2019

Cytori Therapeutics (CYTX) Reports Q3 Loss, Misses Revenue Estimates

Zacks.....»»

Category: topSource: redinewsNov 15th, 2018

Cytori Therapeutics (CYTX) Reports Q3 Loss, Misses Revenue Estimates

Cytori (CYTX) delivered earnings and revenue s.....»»

Category: dealsSource: nytNov 14th, 2018

Entasis Therapeutics reports Q3 net loss ($8.5M) vs. ($8.3M) last year

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallNov 14th, 2018

Capricor Therapeutics (CAPR) Reports Q3 Loss, Lags Revenue Estimates

Zacks.....»»

Category: topSource: redinewsNov 14th, 2018

Jounce Therapeutics, Inc. (JNCE) Reports Q3 Loss, Tops Revenue Estimates

Zacks.....»»

Category: topSource: redinewsNov 13th, 2018

VTv Therapeutics (VTVT) Reports Q3 Loss, Tops Revenue Estimates

vTv Therapeutics (VTVT) delivered earnings and revenue surprises of 60.00% and 63......»»

Category: personnelSource: nytNov 8th, 2018

Flexion Therapeutics (FLXN) Reports Q3 Loss, Tops Revenue Estimates

Flexion Therapeutics (F.....»»

Category: personnelSource: nytNov 7th, 2018

Fate Therapeutics (FATE) Reports Q3 Loss, Lags Revenue Estimates

Fate Therapeutics (FATE) delivered earnings and revenue surprises of -29.17% and -72.98%, respectively, for the quarter ended September 2018.....»»

Category: personnelSource: nytNov 1st, 2018

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Lags Revenue Estimates

Zacks.....»»

Category: topSource: redinewsOct 1st, 2018

Oversold Conditions For Spero Therapeutics (SPRO)

Dividend Channel.....»»

Category: topSource: redinewsSep 13th, 2018

Rancho Cordova"s Cesca Therapeutics reports $27.2 million loss on impairment of assets

Cesca Therapeutics Inc., a Rancho Cordova-based cell therapy company, said it incurred $27.2 million in charges against earnings last quarter for impairment in the value of assets. The impairment charges include $12.7 million to goodwill and $14.5.....»»

Category: topSource: bizjournalsAug 13th, 2018

Abeona Therapeutics (ABEO) Reports Q2 Loss, Lags Revenue Estimates

Abeona Therapeutics (ABEO) delivered earnings and revenue surprises of -56.25% and -54.....»»

Category: worldSource: nytAug 9th, 2018

Spero Therapeutics reports Q2 EPS (69c), consensus (78c)

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 9th, 2018

CytomX Therapeutics (CTMX) Reports Q2 Loss, Tops Revenue Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -2.94% and 29.52%, respecti.....»»

Category: personnelSource: nytAug 8th, 2018